combination therapies

Research in Review

Better Biomarker-Driven Treatment Strategies Needed for NSCLC

08/11/2016

JCP Editors

A trial assessing the clinical effectiveness of biomarker-based treatments provided additional support for the use of targeted therapeutic options, but also called attention to the need for better biomarker-driven...

A...

08/11/2016

Journal of Clinical Pathways

Research in Review

Bortezomib Regimen More Cost Effective Than Current Standard for Mantle Cell Lymphoma

08/05/2016

JCP Editors

Bortezomib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (VR-CAP) may be a more cost-effective treatment option in the United Kingdom for patients with previously untreated mantle cell...

...

08/05/2016

Journal of Clinical Pathways

Research in Review

Immunotherapy Plus Chemotherapy Does not Improve SCLC Outcomes

08/05/2016

JCP Editors

The addition of ipilimumab to etoposide and a platinum agent failed to demonstrate improved survival in patients with extensive-stage small-cell lung cancer when compared with chemotherapy alone, a study published in...

The...

08/05/2016

Journal of Clinical Pathways

Research in Review

Ipilimumab Combination Significantly Improves Melanoma Outcomes

07/27/2016

JCP Editors

Ipilimumab (Yervoy; Bristol-Myers Squibb) combined with local peripheral treatments such as radiotherapy or electrochemotherapy may significantly prolong survival in patients with melanoma compared with...

...

07/27/2016

Journal of Clinical Pathways

Research in Review

Statin Use May Improve Survival in Patients With Lung Cancer

07/11/2016

JCP Editors

Statin use may be associated with improved survival among patients with stage IV non-small cell lung cancer (NSCLC), according to findings from a study published in the journal Lung. Prior studies have shown that...

Statin...

07/11/2016

Journal of Clinical Pathways

Research in Review

Carfilzomib Cost Effective for Myeloma Treatment

06/01/2016

JCP Editors

Carfilzomib, in combination with lenalidomide and dexamethasone (KRd), may be a cost-effective treatment option for patients with relapsed or refractory multiple myeloma, according to the Kyprolis Global Economic...

...

06/01/2016

Journal of Clinical Pathways